Breaking News
Wyeth is now a part of Pfizer Inc. The merger of local Wyeth and Pfizer entities may be pending in various jurisdictions and is subject to completion of various local legal and regulatory obligations. To learn more, please visit www.pfizer.com.

Health Care Professionals Log In

Sign Up for RELISTOR Updates

Gain access to additional content on the RELISTOR Web site and receive updates. You’ll also get at no charge, unlimited access to:

  • The 5–Minute Clinical Consult
  • Epocrates® Online Premium Reference
  • A.D.A.M. QuickSheets

Register Now

$20 Co-Pay Discount

Download coupons for your patients to receive $20 off their prescription of one Retail Kit.

Nurse Resources

Use these resources to help care for your patients

eDetail

Participate in an interactive program, and build a Virtual Sales Brochure.

Indication

RELISTOR is indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Use of RELISTOR beyond
4 months has not been studied.

Important Safety Information

  • RELISTOR is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction
  • If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with RELISTOR and consult their physician
  • Use of RELISTOR has not been studied in patients with peritoneal catheters
  • The most common adverse reactions reported with RELISTOR compared with placebo in clinical trials were abdominal pain (28.5% vs 9.8%), flatulence (13.3% vs. 5.7%), nausea (11.5% vs 4.9%), dizziness (7.3% vs 2.4%), and diarrhea (5.5% vs 2.4%)

Please see the full Prescribing Information.